Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06274515 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

Name: A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies — clinical trial record (NCT06274515)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: REMERGE

StatusRecruiting

PhasePhase 4

SponsorHoffmann-La Roche

Started2024-04-02

View on ClinicalTrials.gov ↗

This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.

Amendment history 2 changes detected by DataLookout

2026-09-05

Primary completion pushed: 2026-09-30 → 2027-12-31

2026-09-05

Completion pushed: 2026-09-30 → 2027-12-31

Trial Details

NCT Number	NCT06274515
Lead Sponsor	Hoffmann-La Roche
Conditions	Breast Cancer
Enrollment	320 participants
Start Date	2024-04-02
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-04